Brain Tumor Clinical Trial
Official title:
Pilot Study to Assess Accuracy of Time-resolved FLT PET and MR Techniques in Determining Treatment-related Necrosis From Recurrent Glioma
The goal of this clinical research study is to learn if using a new imaging solution,
3'-Deoxy-3'-18f-Fluorothymidine, in a positron emission tomography (PET) scan can help
doctors determine if your brain lesion is from the tumor returning or the effects of
previous treatments.
The results of this imaging scan (called an FLT PET scan) will be compared to the results of
a Magnetic Resonance Imaging scan, which you have already had or are scheduled to have
outside of this study.
FLT PET Scan:
If you are found to be eligible to take part in this study, you will have an FLT PET scan.
An FLT PET scan uses the 3'-Deoxy-3'-18f-Fluorothymidine solution, which contains a small
amount of radioactive material. The radioactive nature of the solution allows the scanner to
"see" it in certain places in your body. You will receive the solution by vein through a
catheter. A central venous catheter is a sterile flexible tube that will be placed into a
large vein while you are under local anesthesia. Your doctor will explain this procedure to
you in more detail, and you will be required to sign a separate consent form.
After the injection, you will need to rest quietly until it is time for the scan. The amount
of rest time may vary, but be prepared to wait for about 60 minutes. During the scan, you
will lie flat on your back on a table. After the solution is injected into a vein, the PET
scanner takes pictures of the radioactive solution as it moves through the body and collects
at various sites in the body. By watching how the solution travels through the body and
studying where the solution collects, researchers may be able to learn where the disease is
in your body. The entire procedure should last about 60-70 minutes.
You must not eat or drink anything except water for at least 6 hours before the FLT PET
scan.
About 2 minutes after the FLT solution is injected, blood (about 10 teaspoons) will be drawn
from the catheter. This blood will be drawn to measure how much FLT is in your body and may
help the study staff understand the images better.
Length of Study:
After the FLT PET scan is complete, your active participation on this study will be over.
Follow-Up Medical Record Review:
About 30 days after the FLT PET scan, you will be contacted by phone by the study staff to
check if you are having any side effects. The phone call should last about 15 minutes.
Your medical records will continue to be reviewed for up to an additional 5 years to learn
how you are doing, what other treatments you may have had and how they worked, if you had
any new brain problems, or if the tumor came back.
This is an investigational study. The 3'-Deoxy-3'-18f-Fluorothymidine solution is not FDA
approved or commercially available. At this time, 3'-Deoxy-3'-18f-Fluorothymidine solution
is only being used in research.
Up to 20 patients will take part in this study. All will be enrolled at MD Anderson.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05023434 -
A Study to Measure the Effect of Brain Stimulation on Hand Strength and Function in Patients With Brain Tumors
|
||
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Completed |
NCT02768389 -
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
|
Early Phase 1 | |
| Terminated |
NCT01902771 -
Dendritic Cell Vaccine Therapy With In Situ Maturation in Pediatric Brain Tumors
|
Phase 1 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
| Recruiting |
NCT03286335 -
Local Control, Quality of Life and Toxicities in Adults With Benign or Indolent Brain Tumors Undergoing Proton Radiation Therapy
|
N/A | |
| Recruiting |
NCT05968053 -
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)
|
||
| Recruiting |
NCT05358340 -
Dual Perfusion Imaging for Characterizing Vascular Architecture of Brain Lesions
|
N/A | |
| Terminated |
NCT03276676 -
[18F]Fluciclovine and [18F]FLT PET/CT Assessment of Primary High-Grade Brain Tumors
|
Phase 2 | |
| Completed |
NCT02851355 -
Follow-up Survey of Patients Who Were Treated for Medulloblastoma or Primitive Neuroectodermal Tumors of the Central Nervous in Norway
|
||
| Completed |
NCT02558569 -
The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block
|
Phase 4 | |
| Completed |
NCT02713087 -
Vasopressor Effects in Anesthetized Patients
|
Phase 4 | |
| Completed |
NCT02409121 -
A Novel Health Information Technology System (BMT Roadmap) for Pediatric BMT Patients and Caregivers
|
N/A | |
| Terminated |
NCT02674945 -
Understanding and Improving Quality of Life Through a Wireless Activity Tracker: Observational Phase
|
||
| Withdrawn |
NCT02165995 -
Use of Navigated Transcranial Magnetic Stimulation (nTMS) in Generated Motor and Language Mapping to Evaluate Brain Recovery Following Surgery
|
N/A | |
| Completed |
NCT01171469 -
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
|
Phase 1 | |
| Withdrawn |
NCT01202539 -
Real-time Assessment of Frameless Intrafraction Motion
|
||
| Terminated |
NCT01044966 -
A Study of Intraventricular Liposomal Encapsulated Ara-C (DepoCyt) in Patients With Recurrent Glioblastoma
|
Phase 1/Phase 2 | |
| Completed |
NCT00760409 -
Differentiating Recurrent Brain Tumor Versus Radiation Injury Using MRI
|
N/A | |
| Completed |
NCT00503204 -
Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour
|
Phase 1 |